Since it was first reported in Wuhan, China, in 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic outbreak resulting in a tremendous global threat due to its unprecedented rapid spread and an absence of a prophylactic vaccine or therapeutic drugs treating the virus. The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein is a key player in the viral entry into cells through its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor protein, and the RBD has therefore been crucial as a drug target. In this study, we used phage display to develop human monoclonal antibodies (mAbs) that neutralize SARS-CoV-2. A human synthetic Fab phage display library was panned against the RBD of the SARS-CoV-2 spike protein (SARS-2 RBD), yielding ten unique Fabs with moderate apparent affinities ( EC 50 = 19–663 nM) for the SARS-2 RBD. All of the Fabs showed no cross-reactivity to the MERS-CoV spike protein, while three Fabs cross-reacted with the SARS-CoV spike protein. Five Fabs showed neutralizing activities in in vitro assays based on the Fabs’ activities antagonizing the interaction between the SARS-2 RBD and ACE2. Reformatting the five Fabs into immunoglobulin Gs (IgGs) greatly increased their apparent affinities ( K D = 0.08–1.0 nM), presumably due to the effects of avidity, without compromising their non-aggregating properties and thermal stability. Furthermore, two of the mAbs (D12 and C2) significantly showed neutralizing activities on pseudo-typed and authentic SARS-CoV-2. Given their desirable properties and neutralizing activities, we anticipate that these human anti-SARS-CoV-2 mAbs would be suitable reagents to be further developed as antibody therapeutics to treat COVID-19, as well as for diagnostics and research tools.
【저자키워드】 SARS-CoV-2, monoclonal antibody, Spike protein, Receptor-binding domain, phage display, 【초록키워드】 COVID-19, ACE2, Vaccine, coronavirus, pandemic, Prophylactic, MERS, severe acute respiratory syndrome Coronavirus, virus, anti-SARS-CoV-2, MERS-CoV, angiotensin-converting enzyme 2, viral entry, diagnostics, Spike protein, activity, Antibody therapeutics, cross-reactivity, In vitro assay, Spread, Neutralizing activity, Viral, Receptor-binding domain, Immunoglobulin, outbreak, RBD, SARS-CoV-2 spike protein, Human monoclonal antibody, Wuhan, Research, drug target, avidity, respiratory, moderate, thermal stability, mAbs, mAb, Fab, human monoclonal antibodies, Angiotensin-converting enzyme, Interaction, angiotensin, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, receptor protein, domain, SARS-CoV spike protein, treat, neutralizing activities, IgGs, reagent, Fabs, phage, Effect, FIVE, Cell, neutralize, affinities, Wuhan, China, resulting, develop, caused, significantly, reported, absence, unique, the RBD, apparent affinity, D12, the SARS-CoV-2, therapeutic drug, yielding, 【제목키워드】 Human, coronavirus 2, synthetic, Fab, library, display, Isolated,